Abbott’s HUMIRA® (adalimumab) Approved in the European Union
Abbott (NYSE: ABT) today announced that the European Commission has granted marketing authorization for the use of HUMIRA®, in combination with methotrexate (MTX), as a treatment for active polyarticular juvenile idiopathic arthritis (JIA) in adolescents aged 13 to 17. Additionally, HUMIRA for JIA treatment is approved for those patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Read more ...
New low-dose oral contraceptive YAZ® launched in Europe
Bayer Schering Pharma's YAZ® will be available across Europe as of September 2008. YAZ® is the first oral contraceptive containing 3 mg of the unique progestin drospirenone combined with 0.02 mg of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets followed by 4 days of hormone-free tablets.
Read more ...
GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures.
Read more ...
Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities. As the final step in the divestment of its Oncology portfolio, Nycomed agreed with Bayer Schering Pharma on the sale of a kinase inhibitor program, targeting a key growth and survival pathway in cancer.
Read more ...
GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration
GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science, leading to the development of new medicines.
Read more ...